Pipeline

Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ADCs developed using first-generation technology. Our lead asset, upifitamab rilsodotin (XMT-1536, UpRi), is a first-in-class Dolaflexin ADC in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Our next clinical stage ADC, XMT-1592, a Dolasynthen ADC-targeting NaPi2b expressing tumors entered the clinic in May 2020.

ADC ProgramTargetIndicationPlatformDiscoveryPreclinicalP1P1P2P3
Clinical
upifitamab
rilsodotin (UpRi)*
NaPi2b
Ovarian Cancer Dolaflexin
XMT-1536*
NaPi2b
NSCLC Adenocarcinoma Dolaflexin
Preclinical
XMT-1592*
NaPi2b
Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen
Discovery
XMT-1660
B7-H4
Multiple Solid Tumors Dolasynthen
XMT-2056
Undisclosed
Undisclosed Immunosynthen
Multiple Programs
Undisclosed
Undisclosed Immunosynthen
Multiple Programs
Undisclosed
Undisclosed Dolaflexin or Dolasynthen
Platform Collaborations
Multiple
Multiple
Undisclosed Dolaflexin
ASN004
5T4
Undisclosed Dolaflexin
DrugIndicationStage
Clinical
upifitamab
rilsodotin (UpRi)*
NaPi2b
Ovarian Cancer DolaflexinP1
XMT-1536*
NaPi2b
NSCLC Adenocarcinoma DolaflexinPreclinical
Preclinical
XMT-1592*
NaPi2b
Ovarian Cancer NSCLC Adenocarcinoma DolasynthenPreclinical
Discovery
XMT-1660
B7-H4
Multiple Solid Tumors DolasynthenDiscovery
XMT-2056
Undisclosed
Undisclosed ImmunosynthenDiscovery
Multiple Programs
Undisclosed
Undisclosed ImmunosynthenDiscovery
Multiple Programs
Undisclosed
Undisclosed Dolaflexin or Dolasynthen
Platform Collaborations
Multiple
Multiple
Undisclosed DolaflexinDiscovery
ASN004
5T4
Undisclosed DolaflexinDiscovery
ADC Program Target Indication Platform Phase
XMT-1536* upifitamab rilsodotin (UpRi)* Ovarian Cancer Dolaflexin P2 Pivotal Study
XMT-1536* NaPi2b NSCLC Adenocarcinoma Dolaflexin P1 Proof of Concept
XMT-1592* NaPi2b Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen P1 Dose Escalation
XMT-1660 B7-H4 Multiple Solid Tumors Dolasynthen Preclinical
XMT-2056 Undisclosed Undisclosed Immunosynthen Preclinical
Multiple Programs Undisclosed Undisclosed Immunosynthen Preclinical
Multiple Programs Undisclosed Undisclosed Dolaflexin or Dolasynthen Discovery
Multiple
EMD Logo
Multiple Undisclosed Dolaflexin Preclinical
ASN004
Asana Logo
5T4 Undisclosed Dolaflexin Preclinical

*NaPi2b antibody used in UpRi (formerly XMT-1536) and XMT-1592 is in-licensed from Recepta Biopharma. Recepta has rights to commercialize UpRi and XMT-1592 in Brazil.